Workflow
恒生医疗ETF(513060)近1周新增规模居可比基金首位,港股创新药精选ETF(520690)交投活跃,礼来orforglipron三期临床成功
Xin Lang Cai Jing·2025-08-27 03:57

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing structural opportunities driven by innovative pipeline advancements, capital market recognition, and performance realization, particularly highlighted by the success of Eli Lilly's orforglipron in clinical trials, the inclusion of InnoCare Pharma in multiple indices, and the commercial growth of CanSino Biologics despite increased losses [7]. Group 1: Market Performance - As of August 27, 2025, the Hang Seng Healthcare Index (HSHCI) decreased by 1.96%, with mixed performances among constituent stocks [3] - The Hang Seng Medical ETF (513060) fell by 0.83%, with a latest price of 0.72 yuan, but showed a 0.28% increase over the past week, ranking 1/3 among comparable funds [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) declined by 2.04%, while the corresponding ETF (520690) dropped by 0.88% to 1.02 yuan, but had a 6.89% increase over the past two weeks, ranking 1/2 among comparable funds [5] Group 2: Company Developments - Eli Lilly's orforglipron achieved all primary and key secondary endpoints in the ATTAIN-2 Phase III trial, indicating potential to transform the treatment landscape for obesity in patients with type 2 diabetes [6] - InnoCare Pharma reported a revenue of 1.229 billion yuan in the first half of the year, with a research and development investment of 349 million yuan, and was recently included in major indices, reflecting strong market recognition [6] - CanSino Biologics achieved a revenue of 1.41 billion yuan in H1 2025, a year-on-year increase of 37.8%, but faced an expanded loss of 590 million yuan due to rising R&D and sales expenses [6] Group 3: ETF Insights - The Hang Seng Medical ETF (513060) has seen a significant increase in scale, with a growth of 182 million yuan over the past week, ranking 1/3 among comparable funds [8] - The ETF has a year-to-date Sharpe ratio of 2.41 and has outperformed its benchmark with a year-to-date relative drawdown of 0.63%, the lowest among comparable funds [9] - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Medical ETF is 32.1, indicating it is at a historical low compared to the past three years [9] Group 4: Index Composition - The top ten weighted stocks in the Hang Seng Healthcare Index account for 61.67% of the index, with major players including BeiGene, Innovent Biologics, and WuXi Biologics [9] - The top ten stocks in the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index represent 77.82% of the index, highlighting the concentration of investments in leading biotech firms [11]